XENON PHARMACEUTICALS INC (XENE)

Company Profile

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 251 full-time employees. The company went IPO on 2014-10-17. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). The company is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Company Info

XENON PHARMACEUTICALS INC

3650 Gilmore Way

Vancouver BRITISH COLUMBIA V5G 48W

P: 16044843300

CEO: Simon Pimstone

Employees: 255

Website: https://www.xenon-pharma.com/